
Pharmacologic treatment of phobic disorders, in particular agoraphobia, has been proved to be effective, especially when used in combination with behavior therapy. Favorable responses to tricyclic antidepressants, monoamine oxidase inhibitors, and benzodiazepines have been reported. The limitations of drug therapy for phobias include high dropout rates and the tendency to relapse after discontinuation of therapy. Successful treatment depends on the careful selection of patients and medications and on coordination of drug and behavior therapies.
Benzodiazepines, Monoamine Oxidase Inhibitors, Anti-Anxiety Agents, Phobic Disorders, Behavior Therapy, Humans, Antidepressive Agents, Tricyclic, Agoraphobia, Combined Modality Therapy, Drug Administration Schedule
Benzodiazepines, Monoamine Oxidase Inhibitors, Anti-Anxiety Agents, Phobic Disorders, Behavior Therapy, Humans, Antidepressive Agents, Tricyclic, Agoraphobia, Combined Modality Therapy, Drug Administration Schedule
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 23 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
